Eczema Trial, Recruiting NCT05938478 Sponsor: University of California, San Diego Condition: Eczema
Back to Eczema

Eczema Trial, Recruiting

NCT05938478
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are currently pregnant at the time you sign up
  • You live in the United States or Canada at the time you sign up
  • You give verbal agreement to take part in the OTIS Pregnancy Registry
  • You have been diagnosed with atopic dermatitis (eczema) at the time you sign up
  • You agree to take part in follow-up interviews, possibly a physical exam of your baby (for the first 80 live births in the study), a developmental check for your child, and sharing of your medical records
  • You may qualify for one of three groups: (1) if you have taken the medication tralokinumab at any point during pregnancy or up to about 16 weeks before you conceived; (2) if you have had light therapy or certain other medical treatments for your eczema during pregnancy or shortly before conceiving; or (3) if you have eczema but have not had light therapy or certain other medical treatments during pregnancy or shortly before conceiving

Who may not be able to join:

  • You have already taken part in this study during a previous pregnancy (for the main study groups)
  • You have been exposed to certain medications called methotrexate or mycophenolate mofetil during pregnancy or shortly before conceiving
  • You are signing up after your pregnancy has already ended and you already know the outcome
  • A medical test done before you sign up has confirmed a major physical birth defect in your baby (note: having had a normal or uncertain prenatal screening result does not automatically disqualify you — confirm with trial site)
  • For the second comparison group: you have used tralokinumab, methotrexate, or mycophenolate mofetil during pregnancy or shortly before conceiving
  • For the third comparison group: you have used tralokinumab, methotrexate, mycophenolate mofetil, light therapy, or certain other medical eczema treatments during pregnancy or shortly before conceiving

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 877-311-8972

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
8 December 2022
Est. completion
30 November 2034

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Prevalence of Major Structural Birth Defects

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov